Welcome to our dedicated page for Pressure Bio news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on Pressure Bio stock.
Pressure BioSciences Inc. (PBIO) is a biotechnology innovator specializing in pressure cycling technology (PCT) and UltraShear nanoemulsion platforms. This page provides investors and industry professionals with a comprehensive collection of official announcements, financial disclosures, and scientific developments related to the company's patented methods for enhancing bio-molecular interactions.
Access timely updates on PBIO's advancements in pharmaceutical formulation, nutraceutical delivery systems, and strategic partnerships. Key content includes earnings reports, technology licensing agreements, clinical application progress, and regulatory milestones. All materials are sourced directly from company filings and verified industry channels.
Regularly refreshed content ensures stakeholders maintain current awareness of PBIO's work in creating stable nanoemulsions for improved drug bioavailability. Bookmark this page for efficient tracking of the company's progress in pressure-based biomolecule manipulation techniques and their commercial applications.
Pressure BioSciences (PBIO) announced a partnership with Vita-Forte to create a highly bioavailable multi-antioxidant oral spray using PBIO's UltraShear Technology. The product will combine potent oil-based antioxidants like Acai, Curcumin, and CoQ10 into a fast-absorbing, nanoemulsified spray. Expected to be available by Fall 2024, this product aims to improve antioxidant absorption significantly. Vita-Forte, a leading distributor of superfood ingredients with annual revenues exceeding $20 million, will leverage its extensive customer base to facilitate market introduction and acceptance. This collaboration promises to deliver improved effectiveness and potency for nutraceutical products.
Pressure BioSciences (OTCQB: PBIO) will host a teleconference on June 20, 2024, at 4:30 PM ET to provide updates on various business and financial topics. Key points include the FY 2023 financial and business results, FY 2024 outlook, status of the company's relocation to a new manufacturing facility, and updates on a new Joint Venture Program. The company will also discuss product expansion plans, including new nanoemulsified products expected to release in Q3/Q4 2024, and the placement of first-generation UltraShear benchtop equipment in multiple cannabis companies for THC edible products. Stakeholders can listen live or via replay on the company's website.
Pressure BioSciences (OTCQB: PBIO) announced a teleconference to update stakeholders on June 19, 2024, at 4:30 PM ET. Key topics include FY 2023 financial and business results, the FY 2024 outlook, the status of the company's new manufacturing facility, and updates on Uncle Bud’s Health and Wellness product expansion. New nanoemulsified products are expected to launch commercially in Q3/Q4 2024, including next-generation skincare with nano-retinol, a nootropic enhancer, and a best-in-class antioxidant cocktail. Additionally, the placement of the 1st Generation UltraShear benchtop equipment into cannabis companies will be discussed. The teleconference will include a presentation and a Q&A session. Interested parties can participate live or access a replay via the company's website.
FAQ
What is the current stock price of Pressure Bio (PBIO)?
What is the market cap of Pressure Bio (PBIO)?
